BioVie Inc. (BIVI)

ADDRESS-LC trial is now enrolling patients with Long COVID-related fatigue and cognitive impairment at sites across the U.S. ADDRESS-LC trial is now enrolling patients with Long COVID-related fatigue and cognitive impairment at sites across the U.S.

CARSON CITY, Nev., Aug. 07, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI, BIVIW), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the pricing of its underwritten public offering of 6,000,000 units, with each unit consisting of one share of common stock and one warrant (the “Warrants”) (or pre-funded units in lieu thereof, with each pre-funded unit consisting of one pre-funded warrant (the “Pre-Funded Warrants”) and one Warrant). Each unit is being sold to the public at a price of $2.00 per unit (and each pre-funded unit is being sold to the public at the public offering price of each unit less the $0.0001 per share nominal exercise price for each Pre-Funded Warrant). The gross proceeds to the Company from this offering are expected to be approximately $12 million, before deducting underwriting discounts and commissions and other estimated offering expenses. The Warrants included in the units and pre-funded units have been approved for listing on the Nasdaq Capital Market and are expected to commence trading under the symbol “BIVIW” on August 8, 2025. Each Warrant will be immediately exercisable, will entitle the holder to purchase one share of common stock at an exercise price of $2.50 per share and will expire five years from the date of issuance. Each Pre-Funded Warrant will be immediately exercisable, will entitle the holder to purchase one share of common stock and may be exercised at any time until exercised in full. The common stock (or Pre-Funded Warrants in lieu thereof) and Warrants can only be purchased together in the offering but will be issued separately. The Company has granted the underwriter a 45-day option to purchase up to an additional 900,000 shares of common stock and/or Pre-Funded Warrants and/or Warrants, or any combination thereof, solely to cover over-allotments, if any, at the public offering price, less underwriting discounts and commissions.

Bezisterim treatment appears to be associated with changes in DNA methylation of over 100 genes related to aging and diseases of aging Bezisterim treatment appears to be associated with changes in DNA methylation of over 100 genes related to aging and diseases of aging

Seasoned leaders bring deep expertise in neuroscience drug development, strategic growth, and corporate finance to support BioVie's mission Seasoned leaders bring deep expertise in neuroscience drug development, strategic growth, and corporate finance to support BioVie's mission

Hybrid, decentralized trial of bezisterim in early Parkinson's Disease prioritizes patient access and participation Hybrid, decentralized trial of bezisterim in early Parkinson's Disease prioritizes patient access and participation

CARSON CITY, Nev., June 24, 2025 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that a poster highlighting the decentralized design and patient experience of its Phase 2 SUNRISE-PD clinical trial evaluating bezisterim (NE3107) in early Parkinson's disease will be presented in poster session at the upcoming Advanced Therapeutics in Movement & Related Disorders® Congress , to be held at National Harbor, MD, from June 27 to June 30, 2025.

Squarepoint Ops LLC purchased a new position in shares of BioVie Inc. (NASDAQ:BIVI – Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 14,213 shares of the company’s stock, valued at approximately $28,000. Squarepoint Ops LLC owned about 0.08% of BioVie at the end of the most recent reporting period. Other institutional investors and hedge funds have also modified their holdings of the company. NewEdge Advisors LLC lifted its stake in shares of BioVie by 14,000.0% during the 4th quarter. NewEdge Advisors LLC now owns 14,100 shares of the company’s stock valued at $28,000 after buying an additional 14,000 shares in the last quarter. Northern Trust Corp purchased a new position in shares of BioVie during the 4th quarter valued at $34,000. Two Sigma Investments LP purchased a new position in shares of BioVie during the 4th quarter valued at $57,000. Prosperity Wealth Management Inc. purchased a new position in shares of BioVie during the 4th quarter valued at $63,000. Finally, Bank of Montreal Can purchased a new position in shares of BioVie during the 4th quarter valued at $100,000. Hedge funds and other institutional investors own 4.59% of the company’s stock. BioVie Price Performance Shares of BIVI stock opened at $1.10 on Wednesday. The company has a market capitalization of $20.43 million, a P/E ratio of -0.11 and a beta of 0.77. The company’s 50-day simple moving average is $0.96 and its two-hundred day simple moving average is $1.55. BioVie Inc. has a one year low of $0.62 and a one year high of $7.50. BioVie (NASDAQ:BIVI – Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.17. Analyst Upgrades and Downgrades Separately, Brookline Capital Management upgraded shares of BioVie to a “strong-buy” rating in a report on Tuesday, March 18th. Check Out Our Latest Stock Analysis on BioVie About BioVie (Free Report) BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.

CARSON CITY, Nev., May 14, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that it will host a virtual key opinion leader (KOL) event featuring Suzanne de la Monte, MD, MPH (Brown University Warren Alpert Medical School, Providence VA Medical Center) and Mark Stacy, MD (Medical University of South Carolina College of Medicine), who will join company management to discuss the unmet need and current treatment landscape for Parkinson's disease on Wednesday, May 28, 2025 at 12:00 PM ET. To register, click here.

NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against BioVie Inc. (NASDAQ: BIVI) on behalf of long-term stockholders following a class action complaint that was filed against BioVie on January 19, 2024 with a Class Period from August 5, 2021 to November 29, 2023. Our investigation concerns whether the board of directors of BioVie have breached their fiduciary duties to the company.

CARSON CITY, Nev., March 27, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that it will host a virtual investor event featuring key opinion leader (KOL) Lindsay McAlpine, MD, BSc (Yale University), who will join company management to discuss the unmet need and current treatment landscape for long COVID on Thursday, April 10, 2025 at 10:00 AM ET. To register, click here .

NEW YORK, NY / ACCESS Newswire / January 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BioVie Inc. ("BioVie" or "the Company") (NASDAQ:BIVI). Investors who purchased BioVie securities prior to December 7, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/BIVI.

NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BioVie Inc. ("BioVie" or "the Company") (NASDAQ:BIVI). Investors who purchased BioVie securities prior to December 7, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/BIVI.

NEW YORK, NY / ACCESS Newswire / January 19, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BioVie Inc. ("BioVie" or "the Company") (NASDAQ:BIVI). Investors who purchased BioVie securities prior to December 7, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/BIVI.

NEW YORK, NY / ACCESSWIRE / January 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BioVie Inc. ("BioVie" or "the Company") (NASDAQ:BIVI). Investors who purchased BioVie securities prior to December 7, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/BIVI.

NEW YORK, NY / ACCESSWIRE / January 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BioVie Inc. ("BioVie" or "the Company") (NASDAQ:BIVI). Investors who purchased BioVie securities prior to December 7, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/BIVI.

NEW YORK, NY / ACCESSWIRE / January 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BioVie Inc. ("BioVie" or "the Company") (NASDAQ:BIVI). Investors who purchased BioVie securities prior to December 7, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/BIVI.